Frazier Healthcare Partners
Apr 12, 2018
Cellectis successfully bags USD 164 million for Gene-editing and CAR-T programs
Cellectis successfully bags USD 164 million for Gene-editing and CAR-T programs After a rough journey in 2017, the road seems clear for French CAR-T specialist Cellectis, which has recently closed a USD 164 million U.S. public offering. Out of total funding amount around USD 100 million will be used to build commerc...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
